PNH Clinical Trial
Official title:
A Retrospective Chart Review Study to Evaluate the Impact of Eculizumab in Korean Paroxysmal Nocturnal Hemoglobinuria Patients
Verified date | April 2022 |
Source | Handok Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is a retrospective chart review study, and the main objective of this study is to identify the impact of eculizumab treatment and the improvement of complications before and after eculizumab treatment, and to evaluate the safety during the treatment and the clinical unmet needs during the treatment in PNH patients in real-world.
Status | Completed |
Enrollment | 80 |
Est. completion date | January 3, 2022 |
Est. primary completion date | August 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients with PNH aged 18 years or older who started eculizumab treatment in accordance with drug label between 2012 and January 31st, 2020. (However, patients who have received eculizumab as part of a clinical trial or an expanded access program/compassionate use program prior to 2012 are also eligible.) - Patients who are vaccinated against Neisseria meningitidis at least 2 weeks prior to starting eculizumab treatment. Patients who have been treated with appropriate prophylactic antibiotic therapy for 2 weeks after vaccination if they received eculizumab within 2 weeks after the vaccination. Exclusion Criteria: - Pediatric patients with PNH aged under 18 years - Patients with hypersensitivity to the active ingredients of eculizumab, murine protein, or other components - Patients with untreated severe meningococcal (Neisseria meningitidis) infection - Patients who received other complement inhibitors for PNH before or during eculizumab treatment |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Handok | Seoul |
Lead Sponsor | Collaborator |
---|---|
Handok Inc. |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Decrease of hemolysis after eculizumab treatment | The change in LDH levels before and after eculizumab treatment will be compared to determine whether hemolysis decreased after the treatment. | The results of LDH tests performed before eculizumab treatment, at 6, 12, 24 months after the start of eculizumab treatment, and every 12 months thereafter will be collected. | |
Primary | The Improvement/occurrence of complications and related clinical symptoms before and after eculizumab treatment | The major complications due to PNH include thromboembolism, pulmonary hypertension, renal failure, and smooth muscle spasm, and their occurrence will be determined by the investigator.
In addition, PNH-related symptoms (fatigue, anemia, dysphagia, shortness of breath/dyspnea, chest pain, abdominal pain, erectile dysfunction, hemoglobinuria, others) before and after eculizumab administration will be compared. |
6 months before eculizumab administration to the end of the administration (It is up to subject's treatment period. Through study completion, an average of 51months) | |
Primary | Severity of anemia | Hb levels will be compared to identify the severity of anemia. | Before the administration, at 6, 12, 24 months after the start of the treatment and every and 12 months thereafter | |
Primary | The required Unit of pRBC transfusion before and after eculizumab treatment | From 1 year before the treatment to the end of the administration (It is up to subject's treatment period. Through study completion, an average of 51months) | ||
Primary | Effectiveness Evaluation at Last Follow-Up | The investigator will perform the final evaluation of the efficacy for entire observation period based on the collected data. The investigator will comprehensively judge and evaluate the decrease of hemolysis occurrence, the improvement and occurrence of complications, and the severity of anemia, etc. | At the last follow-up (At the time of data collection retrospectively) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04725812 -
Complement Regulation to Undo Systemic Harm in Preeclampsia
|
Phase 2 | |
Completed |
NCT02598583 -
Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05539248 -
A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03460301 -
Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH
|
N/A | |
Completed |
NCT01412047 -
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
|
N/A | |
Completed |
NCT02605993 -
Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Completed |
NCT05095168 -
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects
|
Phase 1 | |
Terminated |
NCT04702568 -
A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Active, not recruiting |
NCT03531255 -
Pegcetacoplan Long Term Safety and Efficacy Extension Study
|
Phase 3 | |
Not yet recruiting |
NCT06449001 -
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
|
Phase 3 | |
Completed |
NCT03593200 -
A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH
|
Phase 2 | |
Completed |
NCT05884060 -
Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones
|
||
Available |
NCT05982938 -
Danicopan Early Access Program
|